{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Randomization",
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": [
          3,
          14
        ],
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Last Dose"
      },
      {
        "id": "timing_5",
        "name": "Study Treatment Administration",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5,
        "relativeTo": "Baseline"
      },
      {
        "id": "timing_6",
        "name": "TE ADA Additional Follow-up Sampling",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_7",
        "name": "Hypersensitivity Reaction Sampling",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Admission Rescheduling Criteria",
        "instanceType": "Condition",
        "description": "Condition for rescheduling admission to the CRU.",
        "text": "Admission can be rescheduled if PG level is not 90 to 250 mg/dL on Day 1."
      },
      {
        "id": "cond_2",
        "name": "Insulin Infusion Stop Criteria",
        "instanceType": "Condition",
        "description": "Criteria to stop the insulin infusion used to induce hypoglycemia.",
        "text": "Insulin infusion is stopped once bedside PG is <60 mg/dL."
      },
      {
        "id": "cond_3",
        "name": "PG Monitoring Frequency",
        "instanceType": "Condition",
        "description": "Rules for the frequency of bedside plasma glucose monitoring based on the current PG level.",
        "text": "Bedside PG monitoring will be conducted no more than 10 minutes apart while bedside PG is â‰¥90 mg/dL and no more than 5 minutes apart when bedside PG is <90 mg/dL."
      },
      {
        "id": "cond_4",
        "name": "Interim Safety Review Trigger",
        "instanceType": "Condition",
        "description": "The study will pause for a safety review after a specific number of patients have completed Period 2.",
        "text": "Safety data will be reviewed after the first 6 patients (regardless of type of diabetes) are administered LY900018 in Period 2."
      },
      {
        "id": "cond_5",
        "name": "Study Continuation Criteria",
        "instanceType": "Condition",
        "description": "Criteria for continuing the study after the interim safety review.",
        "text": "If no clinically significant safety findings for treatment or study procedure are noted, the remaining patients will be dosed."
      },
      {
        "id": "cond_6",
        "name": "TE ADA Additional Follow-up Trigger",
        "instanceType": "Condition",
        "description": "Criteria for initiating additional follow-up for immunogenicity.",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Patient Replacement",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "Discontinued",
        "toElementId": "Screening",
        "text": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced."
      },
      {
        "id": "trans_2",
        "name": "Transition to TE ADA Follow-up",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "Follow-up",
        "toElementId": "Additional Follow-up",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      },
      {
        "id": "trans_3",
        "name": "Continuation of Inadvertently Enrolled Patient",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If the sponsor or investigator identifies a patient who did not meet enrollment criteria... a discussion must occur... If both agree it is medically appropriate to continue, the investigator must obtain documented approval from the Lilly CP/CRP to allow the inadvertently enrolled patient to continue in the study."
      },
      {
        "id": "trans_4",
        "name": "Discontinuation from TE ADA Follow-up",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Additional follow-up continues until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year after the last dose of study treatment."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Patient Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The patient, or legal representative, requests to be withdrawn from the study."
      },
      {
        "id": "exit_2",
        "name": "Investigator Decision to Discontinue",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The investigator decides that the patient should be discontinued from the study for any reason."
      },
      {
        "id": "exit_3",
        "name": "Discontinuation for External Reasons",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Discontinuation due to enrollment in another clinical study, or for medical, safety, or regulatory reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Study Termination for Safety",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Following the review of the safety data from the first 6 patients to complete Period 2 Day 1, the study will be stopped if deemed necessary for patient safety in the opinion of the Investigator and sponsor."
      },
      {
        "id": "exit_6",
        "name": "Discontinuation of Inadvertently Enrolled Patient",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A patient who did not meet enrollment criteria may be discontinued after discussion between the investigator and sponsor."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Interim Safety Review Decision",
        "timepointId": "After first 6 patients complete Period 2",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to pause and review safety data from the first 6 patients completing Period 2, and to decide whether to continue dosing the remaining patients or stop the study.",
        "conditionIds": [
          "cond_4",
          "cond_5"
        ]
      },
      {
        "id": "dec_2",
        "name": "Inadvertent Enrollment Decision",
        "timepointId": "Upon Discovery",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point upon discovery of an inadvertently enrolled patient to determine if the patient may continue in the study."
      }
    ],
    "summary": {
      "timingCount": 7,
      "conditionCount": 6,
      "transitionRuleCount": 4,
      "exitCount": 6
    }
  }
}